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Highlights 16 
 First report of a feasibility study to inform RCT design in veterinary medicine 17 
 73% of practices had attended ≥1 equine grass sickness (EGS) case in past 2 years 18 
 Higher proportion of EGS-affected premises with recurrent cases in Scotland 19 
 93% of practices would be willing to participate in a field vaccine trial for EGS 20 
 Low EGS incidence, client factors and paperwork cited as barriers to participation   21 
Abstract 22 
Without an experimental model of Equine Grass Sickness (EGS), a randomised controlled 23 
field trial (RCT) represents the only method of evaluating the efficacy of Clostridium botulinum type 24 
C vaccination in preventing naturally occurring disease. Clinical trial feasibility is an important aspect 25 
of preliminary work undertaken prior to initiating RCTs, estimating parameters that are important for 26 
study design. This cross-sectional study aimed to assess the feasibility of conducting a nationwide 27 
RCT of a candidate vaccine for EGS based on responses from a sample of British equine veterinary 28 
practices (n = 119/284).   29 
 30 
Seventy-three percent of practices had attended ≥ 1 EGS case within the preceding two years 31 
(median four cases), and 51.3% regularly attended recurrently affected premises. Veterinary surgeons 32 
had greater confidence diagnosing acute/subacute EGS based solely on history and clinical signs 33 
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compared to chronic EGS.  Ninety-one percent of respondents (n = 103/113) considered the proposed 34 
RCT to be important/very important to equine veterinary research. Ninety-one percent of respondents 35 
(n = 102/112) indicated preparedness to assist in owner recruitment and 92.9% (n = 104/112) 36 
indicated willingness to participate in a RCT. The most frequent reasons for practices declining to 37 
participate were low incidence of EGS (n = 4), did not believe clients would wish to participate (n = 38 
3) and amount of paperwork/data collection involved (n = 2).  There was considerable support 39 
amongst participating veterinary practices for a RCT evaluating the efficacy of Clostridium botulinum 40 
vaccination for the prevention of EGS in Britain. Substantial proportions of participating practices 41 
would be prepared to participate in the RCT and regularly attended EGS-affected premises that would 42 
meet trial inclusion criteria. 43 
 44 
Keywords: Clinical trial; Equine grass sickness; Randomised controlled field trial (RCT); Vaccine. 45 
 46 
Introduction 47 
Equine grass sickness (EGS) is a predominantly fatal neurodegenerative disease affecting 48 
grazing equids, first described in eastern Scotland in the early 1900s (Tocher et al., 1923).  Britain 49 
continues to have the highest incidence of EGS worldwide (Wylie and Proudman, 2009), with 50 
reported incidence rates of 2.1-2.3 cases per 100 horse-years at risk on EGS-affected premises 51 
(Newton et al., 2004; Ireland et al., 2011) and an estimated prevalence of 3.2% in areas of Scotland 52 
(Doxey et al., 1991a).   53 
 54 
It is hypothesised that EGS represents a toxico-infectious form of botulism, with a 55 
combination of risk factors resulting in intestinal overgrowth of and neurotoxin production from 56 
Clostridium botulinum (C. botulinum) type C (Newton et al., 2010). Randomised placebo-controlled 57 
vaccine field trials conducted in 1922-1923, using an antitoxin-neutralised C. botulinum toxin, 58 
demonstrated a marked reduction in EGS incidence in vaccinated animals (Tocher, 1924). Lower 59 
serum antibody titres to C. botulinum type C surface antigens and C. botulinum C1 neurotoxin 60 
(BoNT/C) were identified in EGS cases compared to controls (Hunter et al., 1999) and a subsequent 61 
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case-control study reported that increasing antibody titres to C. botulinum type C and BoNT/C toxoid 62 
were significantly associated with decreased risk of EGS (McCarthy et al., 2004). Additionally, horses 63 
previously in contact with an EGS case were reported to be at reduced risk, potentially indicating that 64 
non-fatal exposure to the causative agent may induce some degree of resistance (Wood et al., 1998). 65 
Currently, there is no model to reproduce EGS experimentally, precluding the use of experimental 66 
challenge studies and therefore a field trial represents the only available method to test the hypothesis 67 
that C. botulinum type C toxico-infection causes EGS and of evaluating the effect of vaccination in 68 
the prevention of naturally occurring disease (Hedderson and Newton, 2004). 69 
 70 
The randomised controlled trial (RCT) is considered as the best instrument to evaluate the 71 
effectiveness of medical interventions (Oude Rengerink et al., 2010). Clinical trial feasibility is a 72 
process of evaluating the possibility of conducting a particular trial in a specific geographical region 73 
(Rajadhyaksha, 2010), and is an important first step in initiating a RCT. In human clinical trials, 74 
investigator/site selection questionnaires and feasibility checklists are frequently employed to identify 75 
potential trial sites and participants. Feasibility studies are considered to be particularly important for 76 
RCTs investigating interventions for rare diseases (Hickey et al., 2010). 77 
 78 
In order to inform the design of a nationwide randomised, placebo-controlled field trial of a 79 
candidate vaccine against EGS in Britain, this cross-sectional feasibility study aimed to identify 80 
practices attending premises with high EGS incidence rates and to explore attitudes of veterinary 81 
surgeons towards the proposed RCT.   82 
 83 
Materials and methods 84 
Selection of study sample 85 
Non-probability sampling was used, with all veterinary practices (n = 200) registered with a 86 
nationwide EGS surveillance scheme covering England, Scotland and Wales (Wylie et al., 2011) 87 
being invited to participate.  Additionally, from the database of referring veterinary practices held by 88 
the Diagnostic Laboratory Services at the Animal Health Trust, a further 84 practices (located in 89 
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England, Scotland and Wales) with equine clients were identified and the principal partners were 90 
invited to participate. 91 
 92 
Questionnaire design 93 
The self-administered postal questionnaire was designed using an automated data capture 94 
system (Autonomy, TeleForm version 10.2) (Supplementary material 1).  The questionnaire contained 95 
a study synopsis pertaining to the proposed protocol for a nationwide RCT of a candidate vaccine for 96 
EGS. The questionnaire was pretested amongst a group of veterinary surgeons, who were not enrolled 97 
on the study, and revised in accordance with their comments. The questionnaire was accompanied by 98 
a reply-paid envelope and a hand-signed covering letter that assured confidentiality and provided the 99 
principal investigator’s name, address, telephone number and email address. To maximise response 100 
rates, reminder postcards were sent to non-respondents 8 weeks after the initial mailing, followed by a 101 
second questionnaire mailing 6 weeks after the reminder postcards to remaining non-respondents.   102 
 103 
Data analysis 104 
Questionnaire data were scanned and verified using TeleForm then exported to Microsoft 105 
Excel.  Statistical analyses were performed using commercial software (SPSS version 21). Data are 106 
described as medians with interquartile ranges (IQR) for continuous data and as proportions with 95% 107 
confidence intervals (CI) for categorical data. Pearson Chi-squared or Fisher’s exact tests were used to 108 
assess associations between categorical variables.  Kruskal-Wallis or Mann-Whitney U tests were 109 
used to test the statistical significance of differences in median values of continuous variables 110 
between categories of categorical variables. Critical probability was set at 0.05. 111 
 112 
Results 113 
Description of responses 114 
Of the 284 questionnaires mailed, 119 useable responses (41.9%) were returned, with a 115 
further three non-useable responses received from practices declining to participate due to limited 116 
numbers of EGS cases seen by the practice.  Detailed descriptions of responses and characteristics of 117 
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responding practices are available as supplementary information (items 2 and 3).  Comparison of 118 
respondents with non-respondents found no association between response rate and country (England, 119 
Scotland or Wales) (P = 0.40), type of practice (P = 0.13) or registration with the EGS surveillance 120 
scheme (P = 0.10).  121 
 122 
Of the 119 responding practices, 2.5% (n = 3; 0-5.3%) no longer undertook equine work, and 123 
these responses were excluded from further data analysis.  Thirty-eight percent (n = 44/116; 29.1-124 
46.8%) of practices were equine-only; 49.1% (n = 57; 40.0-58.2%) were mixed practices with < 50% 125 
equine work and 12.9% (n = 15; 6.8-19.0%) were mixed practices with ≥ 50% equine work.  The 126 
majority were first opinion practices (69.8%; n = 81; 61.5-78.2%).  The number of registered 127 
horses/ponies differed with proportion of equine work: equine-only practices had a median of 5,250 128 
horses/ponies (IQR 2,075-10,000), mixed practices with ≥ 50% equine work had a median of 4,812 129 
horses/ponies (IQR 1,500-13,684) and mixed practices with < 50% equine work had a median of 130 
1,000 horses/ponies (IQR 358-2,000) (P < 0.001). 131 
 132 
Veterinary surgeon experience of EGS 133 
The majority of respondents reported that their practice had attended ≥ 1 EGS case within the 134 
preceding two years (73.0%; n = 84/115; 64.9-81.1%; Figure 1), with a median of four cases (IQR 2-135 
7; range 1-20).  A greater proportion of equine-only practices (90.7%; n = 39/43; 82.0-99.4%) 136 
reported attending ≥ 1 EGS case within the preceding two years compared to mixed practices (61.6%; 137 
n = 45/73; 50.5-72.8%) (P = 0.002).  Using the estimated total number of registered horses/ponies, the 138 
median EGS period prevalence for the preceding two years was 0.08% (IQR 0.005-0.25%; range 0-139 
3.0%).  The period prevalence in Scotland was higher (median 0.5%; IQR 0.25-1.0%) compared to 140 
England (median 0.05%; IQR 0.005-0.17%) or Wales (median 0.03%; IQR 0.005-0.07%) (P = 0.005).  141 
Excluding practices reporting no EGS cases in the previous two years, the median period prevalence 142 
was 0.12% (IQR 0.02-0.3%; range 0.009-3.0%).   143 
 144 
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The majority of respondents indicated they could readily identify premises attended by their 145 
practice that had been affected by EGS within the preceding two years (68.8%; n = 77/112; 60.2-146 
77.3%), with a greater proportion of equine-only practices (81.0%; n = 34/42; 69.1-92.8%) able to 147 
identify EGS-affected premises compared to mixed practices (61.4%; n = 43/70; 50.0-72.8%) (P = 148 
0.03).  Fifty-one percent of respondents (n = 56/109; 42.0-60.8%) indicated their practice regularly 149 
attended premises recurrently affected by EGS.  There was an association between country and 150 
recurrent premises (P = 0.001), with 92.3% of practices in Scotland (n = 12/13; 77.8-100%) able to 151 
identify recurrent premises, compared to 47.8% of practices in England (n = 44/92; 37.6-58.0%) and 152 
none of the practices in Wales (n = 0/4; 0-0.49%).  153 
 154 
The majority of respondents reported that their practice provided recommendations for 155 
management on EGS-affected premises.  The most frequently recommended preventive management 156 
strategies were minimising pasture disturbance, removal of horses/ponies from affected fields for a 157 
specified period of time and prioritising preventive measures at high risk times of year and/or for high 158 
risk groups of horses/ponies (Table 1).   159 
 160 
Respondents indicated that veterinary surgeons within their practice were more confident 161 
diagnosing the acute or subacute clinical subtypes of EGS based solely on history and clinical signs 162 
compared to cases of chronic EGS (Table 2).  For diagnosis of acute/subacute EGS, a greater 163 
proportion of respondents from equine-only practices (81.4%; n = 35/43; 69.8-93.0%) indicated that 164 
veterinary surgeons within their practice were confident/very confident based solely on history and 165 
clinical signs compared to respondents from mixed practices (63.0%; n = 46/73; 51.9-74.1%) (P = 166 
0.04).  Similarly, for diagnosis of chronic EGS, a greater proportion of respondents from equine-only 167 
practices (69.8%; n = 30/43; 56.0-83.5%) indicated that veterinary surgeons within their practice were 168 
confident/very confident based solely on history and clinical signs compared to respondents from 169 
mixed practices (45.1%; n = 32/71; 33.5-56.6%) (P = 0.01).  For diagnosis of acute/subacute EGS, the 170 
median number of EGS cases attended within the preceding two years was greater where veterinary 171 
surgeons were reported to be confident/very confident compared to those reported to be not/somewhat 172 
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confident (median 4 cases, IQ 2 – 7 cases and median 2, IQ 0 – 3 cases, respectively) (P < 0.001).  173 
The median number of EGS cases attended within the preceding two years was also greater where 174 
veterinary surgeons were reported to be confident/very confident in the clinical diagnosis of chronic 175 
EGS compared to those reported to be not/somewhat confident (median 5 cases, IQ 2 – 9 cases and 176 
median 2, IQ 0 – 4 cases, respectively) (P < 0.001). The most frequently reported ante-mortem 177 
ancillary diagnostic tests used in the investigation of suspected cases of EGS were phenylephrine eye 178 
drops and routine haematology and biochemistry (Table 2).  179 
 180 
Potential participation in EGS vaccine RCT 181 
When asked about the feasibility of undertaking certain aspects of clinical assessments, 182 
treatment administration and data collection, the majority of respondents indicated that the proposed 183 
RCT protocol would be feasible (Table 3).   184 
 185 
Overall, 99.1% of respondents (n = 111/112; 97.4-100%) indicated willingness to participate 186 
in the RCT if a client registered with their practice wished to enrol, and 72.3% of respondents (n = 187 
81/112; 64.0-80.6%) indicated that they would recommend participation in the RCT to all clients 188 
keeping horses/ponies on EGS-affected premises, with a further 26.8% (n = 30/112; 18.6-35.0%) 189 
indicating that they would recommend participation to selected equine clients.   190 
 191 
The majority of respondents (85.8%; n = 91/106; 79.2-92.5%) indicated that if they owned a 192 
horse/pony they would be willing to enrol them in the RCT.  Similarly, 85.5% of respondents (n = 193 
94/110; 78.9-92.0%) indicated that they would be prepared to enrol a horse/pony owned by a family 194 
member or close friend in the RCT.  Respondents believed the proposed RCT was of greatest 195 
importance for equine veterinary research, with a lower proportion of respondents considering the 196 
RCT was important to their practice equine population (Figure 2).  Should a vaccine demonstrated to 197 
be effective in the prevention of EGS be available, 48.6% of respondents (n = 54/111; 39.3-57.9%) 198 
would recommend its use to all equine clients registered with their practice.  A further 37.8% (n = 199 
42/111; 28.8-46.9%) would recommend vaccination to all clients keeping horses/ponies on EGS-200 
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affected premises and 11.7% (n = 13/111; 5.7-17.7%) would recommend vaccination to selected 201 
clients.   202 
 203 
Ninety-one percent of respondents (n = 102/112; 85.8-96.4%) indicated preparedness to assist 204 
in recruitment of owners for the RCT. Overall, 92.9% of respondents (n = 104/112; 88.1-97.6%) 205 
indicated willingness to participate in the RCT.  Reasons given by the eight negative respondents 206 
were: the RCT was not relevant to practice caseload/low EGS incidence (n = 4); they did not believe 207 
clients would wish to participate (n = 3); they considered that there would be too much paperwork 208 
involved (n = 2); the RCT was too great a time commitment (n = 1); they were not interested in the 209 
RCT/EGS (n = 1); concerns over causal association between C. botulinum type C and EGS and 210 
limited available safety data (n = 1); and forthcoming personnel changes at the practice (n = 1).   211 
 212 
Discussion 213 
Clinical trial feasibility studies are not widely used in veterinary medicine, yet a site 214 
feasibility survey represents a small expenditure, in terms of both time and financial cost, and can 215 
provide invaluable information to inform RCT study design. The key findings from this feasibility 216 
study are that the majority of participating veterinary practices could readily identify EGS-affected 217 
premises and would be prepared to consider entering animals under their care into an RCT 218 
investigating the efficacy of C. botulinum type C vaccination in the prevention of naturally occurring 219 
EGS. This study also provided important information about reasons why veterinary surgeons may not 220 
wish to enter this trial. To the authors’ knowledge, this is the first report of using a site feasibility 221 
study to inform the design of a RCT in veterinary medicine.  222 
 223 
Non-probability sampling was used to identify the accessible population of veterinary 224 
practices invited to participate in this study, thereby introducing selection bias. However, purposive 225 
sampling of all veterinary practices registered with the EGS surveillance scheme (Wylie et al., 2011) 226 
facilitated assessment of the usefulness of the scheme for recruitment of horses to the proposed EGS 227 
RCT. The useable response rate to the postal questionnaires of 41.9% was disappointing and may 228 
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have introduced further selection bias; however it is comparable to response rates achieved in other 229 
questionnaire surveys of equine veterinary surgeons (Savage et al., 1998; Price et al., 2002; Hewson et 230 
al., 2007; Mair and White, 2008). 231 
 232 
With the aim of maximising response rate and minimising non-response bias, many elements 233 
of the tailored design method (Dillman, 2007) were utilised in the administration of this survey.  234 
These included the use of personalised cover letters, sending questionnaires by first class post and 235 
providing non-respondents with a second copy of the questionnaire, which were all reported in a 236 
systematic review as methods that significantly increase response rates to postal questionnaires 237 
(Edwards et al., 2002). The risk of errors introduced by responder bias is a well-recognised limitation 238 
of all questionnaire-based research and in this study respondents are likely to be individuals with a 239 
particular interest in EGS, and not, therefore, a representative sample of the equine veterinary 240 
profession in the UK. Although not statistically significant, comparison of respondents with non-241 
respondents identified that a greater proportion of practices registered with the EGS surveillance 242 
scheme responded than other practices invited to participate in the study. However, it is unlikely that 243 
practices rarely attending cases of EGS would elect to register with the surveillance scheme and 244 
practices in regions with lower EGS incidence are likely to be under-represented in this study.  245 
Although this degree of response bias precludes direct extrapolation of this study’s findings to all 246 
veterinary practices undertaking equine work in Britain, it does support use of the surveillance scheme 247 
in recruiting practices as site investigators for the proposed EGS RCT. 248 
 249 
Both equine-only and mixed practices were represented in the study population, with the 250 
majority of respondents working in solely first opinion practices. As might be expected, equine-only 251 
practices had greater numbers of registered horses, and a larger proportion had attended EGS cases 252 
within the study period.  Ante-mortem diagnosis of EGS is often presumptive, based on a combination 253 
of historical epidemiological information and clinical signs. However clinical signs exhibited are 254 
often diverse, varying with disease severity, and no clinical sign is pathognomonic for all forms of the 255 
disease (Doxey et al., 1991b).  In addition, many of the clinical signs observed may also occur in a 256 
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substantial proportion of colic cases (Doxey et al., 1991b), and it may be difficult to differentiate 257 
acute/subacute EGS from other causes of colic particularly in areas where the disease is less prevalent 258 
(Milne, 1996). In this study, respondents indicated a greater degree of confidence making a clinical 259 
diagnosis of acute/subacute EGS compared to cases of chronic EGS. Veterinary surgeons from 260 
equine-only practices were more confident in the clinical diagnosis of EGS compared to those from 261 
mixed practices, which may reflect the increased likelihood of these respondents having recent 262 
experience of the disease. Furthermore, veterinary surgeons that were confident in diagnosing EGS 263 
based solely on history and clinical signs had attended a greater number of EGS cases within the 264 
preceding two years.   265 
 266 
Prevalence of EGS was greatest in Scotland, consistent with historical reports (Guthrie, 1940; 267 
Gilmour and Jolly, 1974), and in keeping with more recent data, a significantly greater proportion of 268 
Scottish practices regularly attended EGS-affected premises with a history of disease recurrence 269 
(Wylie et al., 2011). Given the small proportion of respondents indicating that suspected cases of EGS 270 
attended by their practice were definitively diagnosed via histopathology, misclassification bias may 271 
have resulted in overestimation of EGS prevalence in this study. Additionally, diagnostic suspicion 272 
bias, where exposure is taken as a diagnostic criterion, may influence the EGS prevalence reported in 273 
the current study (Delgado-Rodríguez and Llorca, 2004; Sackett 1979). For example, veterinary 274 
surgeons’ knowledge of a horse’s prior exposure to EGS risk factors, particularly on recurrently 275 
affected premises, may influence their subsequent diagnostic process where EGS is suspected.  276 
However, where veterinary surgeons have experience of EGS, diagnostic accuracy based on 277 
signalment, historical and clinical findings, is considered to be high (Pirie 2006), and accuracy of 278 
clinical diagnosis in cases of chronic EGS has been reported as 100% (Doxey et al., 1998).   279 
 280 
Numerous epidemiological studies have identified an array of risk factors for EGS (recently 281 
reviewed by Pirie et al. (2014)), and in the absence of any available preventive healthcare measure 282 
current recommendations focus on implementation of management strategies designed to minimise 283 
exposure to risk factors. The majority of respondents in this study provided management advice for 284 
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EGS-affected premises, predominantly pertaining to pasture management, reducing access to the 285 
EGS-affected paddock and prioritising preventive management strategies for high risk animals, and 286 
particularly where respondents had attended EGS cases within the preceding 2 years. Premises where 287 
pasture had been disturbed, for example through construction work or moles, within the previous 12 288 
months had higher odd of an EGS case occurring compared to pastures that had not been disturbed 289 
(odd ratio 3.4) (McCarthy et al., 2004b), and minimising pasture disturbance and soil exposure was 290 
the most frequent recommendation by respondents in this study. Over 30% of respondents advised 291 
some degree of restricted grazing of EGS-affected paddocks, consistent with several studies reporting 292 
increased risk of EGS occurrence with access to grazing, particularly on pastures with a previous 293 
history of EGS (Gilmour and Jolly, 1974; Doxey et al., 1991; Wood et al., 1998; McCarthy et al., 294 
2004a).  Previous studies have reported increased risk of EGS in young adults (Gilmour and Jolly, 295 
1974; Doxey et al., 1991; Wood et al., 1998; McCarthy et al., 2004a; Newton et al.; 2004), and in 296 
animals that have recently moved to new premises or pasture (Gilmour and Jolly, 1974; Doxey et al., 297 
1991; Wood et al., 1998; McCarthy et al., 2004a), and 42% of respondents advised prioritising 298 
preventive management strategies for animals within these higher risk groups. It is likely that a 299 
substantial proportion of EGS-affected premises will implement preventive management strategies in 300 
order to try to reduce the risk of recurrence. his needs to be taken into consideration as a potential bias 301 
when designing protocols for any intervention for EGS, including a vaccine RCT. An appropriately 302 
conducted RCT, with random treatment group allocation performed at premises level, would facilitate 303 
controlling for these management-level risk factors. 304 
 305 
Poor investigator compliance with trial protocols can have important effects on the overall 306 
result (Prescott et al., 1999). Poor design of data collection methods, excessive data collection and 307 
follow-up have been cited by clinicians as impediments to patient recruitment in human trials (Benson 308 
et al., 1991; Coombs et al., 1993). In the current study, of the small number of respondents not willing 309 
to participate in the proposed EGS RCT, 25% considered that there would be too much paperwork 310 
involved. The majority of respondents indicated that data collection, clinical assessments and 311 
treatment administration aspects of the proposed RCT protocol would be feasible for their practice to 312 
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undertake (Table 3), implying that attaining good compliance with the trial protocol would be 313 
achievable. A substantial proportion of respondents indicated that provision of clerical support or 314 
additional remuneration would be required for data collection, and that availability of veterinary 315 
support for the treatment administration phase would be desirable. Ensuring these factors are 316 
considered in both the design and financial requirements for the proposed RCT will help to maximise 317 
veterinary investigators’ compliance with the trial protocol.   318 
 319 
In a survey of healthcare professionals, 17% indicated that scientifically uninteresting trials 320 
were an impediment to recruitment (Foley and Moertel, 1991). Questions addressed by RCTs should 321 
be interesting and relevant to practice (Fletcher et al., 2012) and of sufficient importance to clinicians 322 
for them to be willing to take part and comply with protocol requirements (Prescott et al., 1999).  323 
While only 49% of respondents in the current study considered a nationwide RCT of a candidate 324 
vaccine against EGS would be important to their own practice, 91% considered that this RCT would 325 
be important to equine veterinary research.   326 
 327 
The majority of respondents indicated willingness to assist in recruitment of horse owners for 328 
the proposed RCT, and a large proportion indicated that they would recommend participation to 329 
owners registered with their practice should one of their clients enrol in the trial. The reasons given by 330 
those not wishing to aid in the recruitment phase were consistent with factors frequently reported to 331 
act as barriers to the recruitment activity of clinicians in human clinical trials (Prescott et al., 1999; 332 
Ross et al., 1999). In order to assess the overall acceptability of the proposed RCT, respondents were 333 
asked whether or not they would enrol their own animal, or a horse/pony owned by a family member 334 
or close friend, with the majority responding positively to both scenarios.   335 
 336 
Ninety-three percent of respondents indicated willingness to participate in the RCT, with a 337 
greater proportion indicating that they would take part should a client wish to enrol. Most respondents 338 
to the current study indicated that they would recommend the use of vaccination in the prevention of 339 
EGS, should an effective vaccine be available. As with barriers to recruitment, reasons given by 340 
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respondents for not wishing to participate in the proposed RCT were broadly similar to factors 341 
affecting clinician decisions regarding taking part in clinical trials (Prescott et al., 1999; Ross et al., 342 
1999). Clinician concerns about adverse effects of treatment or the burden to patients were cited as 343 
important factors in deciding whether or not to take part in cancer clinical trials (Foley and Moertel, 344 
1991). While these factors were considered important barriers by a very low number of respondents in 345 
this study, ensuring safety data are available and addressing protocol-related barriers to owner 346 
participation should be incorporated in the design of the proposed RCT. 347 
 348 
Conclusions 349 
The results of this study indicate that undertaking a RCT evaluating the efficacy of C. 350 
botulinum vaccination for the prevention of EGS in Britain would be feasible, with considerable 351 
support for such a trial demonstrated amongst participating veterinary surgeons.  Results provided an 352 
estimate of the proportions of practices attending EGS-affected premises that would meet inclusion 353 
criteria and would be prepared to participate in the proposed RCT, both of which were high despite a 354 
low overall estimated prevalence of EGS.  The study also provided information regarding aspects of 355 
trial design that might make it more acceptable.   356 
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Figure legends 510 
Figure 1: Map of the geographical distribution of veterinary practices, attending no or ≥1 EGS cases 511 
within the preceding two years, participating a survey of veterinary surgeons in Britain (n=116). 512 
 513 
Figure 2: Veterinary surgeons’ opinions regarding the potential importance of a proposed RCT of a 514 
vaccine for the prevention of EGS reported in a survey of veterinary surgeons in Britain (n=113). 515 
 516 
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Table 1: Preventive management measures currently recommended for EGS-affected premises in a 518 
survey of veterinary surgeons in Britain (n=116). 519 
Preventive management strategies 
recommended for EGS-affected 
premises 
Frequency 
(all respondents n=113) 
Percent 
(95% CI) 
Frequency 
(only respondents seeing EGS 
in last 2 years n=84) 
Percent 
(95% CI) 
None 18 
15.9  
(9.2-22.7) 
7 
8.4 
(2.4-14.2) 
Remove horses permanently from affected 
paddock/field 
21 
18.6 
(11.4-25.8) 
13 
15.7 
(7.7-23.2) 
Remove horses from affected 
paddock/field for specified time period 
59 
44.2 
(43.0-61.4) 
44 
53.0 
(41.7-63.1) 
Reduce time spent grazing affected 
paddock/field 
34 
30.1 
(21.6-38.5) 
30 
36.1 
(25.5-46.0) 
Avoid sudden dietary changes 41 
36.3 
(27.4-45.1) 
34 
41.0 
(30.0-51.0) 
Provide supplementary forage 42 
37.2 
(28.2-46.1) 
37 
44.6 
(33.4-54.7) 
Avoid overuse of ivermectin anthelmintics 17 
15.0 
(8.5-21.6) 
16 
19.3 
(10.6-27.4) 
Co-graze with ruminants 20 
17.7 
(10.7-24.7) 
19 
22.9 
(13.7-31.6) 
Avoid stressful incidents 29 
25.7 
(17.6-33.7) 
22 
26.5 
(16.8-35.6) 
Minimise soil exposure and pasture/soil 
disturbance  
69 
61.1 
(52.1-70.1) 
56 
67.5 
(56.6-76.7) 
Hand removal of faeces (not mechanical) 38 
33.6 
(24.9-42.3) 
29 
34.9 
(24.4-44.7) 
Prioritise preventive measures at high risk 
times of year 
45 
39.8 
(30.8-48.8) 
39 
47.0 
(35.8-57.1) 
Prioritise preventive measures for high risk 
animals (e.g. young adults, new arrivals) 
47 
41.6 
(32.5-50.7) 
40 
48.2 
(36.9-58.3) 
Other preventive measure* 6 
5.3 
(1.2-9.4) 
6 
7.2 
(1.6-12.6) 
*Other preventive measures included calling EGS Fund for latest advice; minimise time spent on wet/flooded 520 
areas; monitor stock density vs sward height; move to new premises; mechanical faecal removal employed and 521 
providing supplementary selenium and limestone flour. 522 
  523 
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Table 2: Level of confidence in diagnosis of EGS based on case history and clinical signs alone and 524 
ancillary diagnostic test utilised in the investigation of suspected EGS cases reported in a survey of 525 
veterinary surgeons in Britain (n=116). 526 
Level of confidence in diagnosis based on 
history and clinical signs alone 
Acute/ 
Subacute (n=116) 
Frequency (%; 95% CI) 
Chronic (n=114) 
Frequency         (%; 
95% CI) 
Not confident 4 (3.4; 0.1-6.8) 9 (7.9; 2.9-12.8) 
Somewhat confident 31 (26.7; 18.7-34.8) 43 (37.7; 28.8-46.6) 
Confident 53 (45.7; 36.6-54.8) 44 (38.6; 29.7-47.5) 
Very confident 28 (24.1; 16.4-31.9) 18 (15.8; 9.1-22.5) 
Ancillary/diagnostic test used in the 
investigation of suspected EGS cases 
Acute/ 
Subacute (n=87) 
Frequency (%) 
Chronic (n=84) 
Frequency (%) 
None 2 (2.3; 0-5.4) 4 (4.6; 0.2-9.3) 
Phenylephrine eye drops 42 (48.3; 37.8-58.8) 42 (50.0; 39.3-60.7) 
Routine haematology/biochemistry 24 (27.6; 18.2-37.0) 31 (35.6; 26.6-47.2) 
Nasogastric intubation 23 (26.4; 17.2-35.7) 10 (11.5; 5.0-18.8) 
Exploratory laparotomy +/- ileal biopsy 20 (23.0; 14.1-31.8) 21 (24.1; 15.7-34.3) 
Rectal examination 17 (19.5; 11.2-27.9) 10 (11.5; 5.0-18.8) 
Abdominocentesis 17 (19.5; 11.2-27.9) 16 (18.4; 10.6-27.4) 
Post mortem examination 14 (16.1; 8.4-23.8) 5 (5.7; 0.9-11.0) 
Abdominal ultrasonography 4 (4.6; 0.2-9.0) 6 (6.9; 1.6-12.6) 
Endoscopy  4 (4.6; 0.2-9.0) 4 (4.6; 0.2-9.3) 
Rectal biopsy  2 (2.3; 0-5.4) 5 (5.7; 0.9-11.0) 
Faecal worm egg count 2 (2.3; 0-5.4) 2 (2.3; 0-5.6) 
Other ancillary/diagnostic tests* 3 (3.4; 0-7.3) 11 (12.6; 5.9-20.3) 
*Other ancillary/diagnostic tests for acute/subacute EGS cases included barium oesophogram, faecal analysis 527 
and lack of response to treatment (all n=1); other ancillary/diagnostic tests for chronic EGS cases included 528 
gastroscopy/gastroduodenoscopy (n=2), oral glucose absorption test (n=4), faecal analysis (n=2), barium 529 
oesophogram (n=1), full dental examination (n=1) and weight loss investigation (n=1).  530 
  531 
Page 19 of 20
20 
 
Table 3: Veterinary surgeons’ opinions regarding aspects of data collection, clinical assessment and 532 
treatment administration for a proposed RCT of a vaccine for the prevention of EGS reported in a 533 
survey of veterinary surgeons in Britain (n=116). 534 
Veterinary surgeon participation in proposed EGS 
vaccine field trial (RCT) 
Frequency (%; 95% CI) 
Yes 
 
Yes, with 
additional support 
and/or fees 
provided 
 
No 
 
Would it be feasible for veterinary surgeons at your practice 
to complete standardised recording forms for each clinical 
examination during the RCT? (n=114) 
67  
(58.8; 49.7-67.8) 
45  
(39.5; 30.5-48.4) 
2  
(1.8; 0-4.2) 
Would it be feasible for veterinary surgeons at your practice 
to complete standardised recording forms for any suspected 
adverse event during the RCT? (n=114) 
54  
(47.4; 38.2-56.5) 
58  
(50.9; 41.7-60.1) 
2  
(1.8; 0-4.2) 
Would it be feasible for veterinary surgeons at your practice 
to inform RCT staff immediately regarding any suspected 
EGS cases attended? (n=114) 
114  
(100.0; 96.8-100.0) 
N/A 0 
Would it be feasible for veterinary surgeons at your practice 
to inform RCT staff immediately regarding any cases of 
mortality occurring in horses/ponies enrolled in the RCT? 
(n=113) 
113  
(100.0; 96.8-100.0) 
N/A 0 
Would your practice be willing to help RCT staff facilitate 
the collection and transportation of fatal cases of suspected 
EGS for post mortem examination? (n=113) 
108  
(95.6; 91.8-99.4) 
N/A 
5  
(4.4; 0.6-8.2) 
 
Yes 
 
Yes, only if 
accompanied by 
vet from practice 
No 
 
For suspected EGS cases, would your practice allow 
additional clinical examinations undertaken by RCT staff? 
(n=113) 
92  
(81.4; 74.2-88.6) 
21  
(18.6; 11.4-25.8) 
0 
 
All treatments 
administered by 
practice vets 
All treatments 
administered by 
practice vets with 
support from 
locums as required 
All treatments 
administered by 
dedicated, 
specifically trained 
RCT locum vet 
Which option would you prefer for administration of RCT 
treatments for horses/ponies under the care of your practice? 
(n=110) 
51  
(46.4; 37.0-55.7) 
57  
(51.8; 42.5-61.2) 
2  
(1.8; 0-4.3) 
 535 
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